Skip to content
Toggle main navigation
Home
More
Open dropdown to see remaining menu items
Log in
Webinar: Mastering challenges in iPSC-derived allogeneic cell drug product manufacturing
Published on April 14, 2025
Continue reading on website
Other news
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies
April 10, 2025
Belgium, Mont Saint-Guibert, April 10 – Cellistic , a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases.Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages
Scaling NK Cell manufacturing: From iPSCs to NK cells in a feeder-free, GMP-ready platform
April 16, 2025
Natural Killer (NK) cell treatments are not readily accessible to patients due to persistent manufacturing complexities, scalability issues, and challenges in delivery. Cellistic's iPSC-based allogeneic Echo™-NK Manufacturing Platform breaks down these barriers by enabling therapeutic developers to manufacture safe, consistent, and cost-efficient off-the-shelf NK cell therapies at scale.
